OTC Stock Overview
Engages in research, development, production, and sale of vision enhancement products in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Ocumetics Technology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.32 |
| 52 Week High | CA$0.40 |
| 52 Week Low | CA$0.25 |
| Beta | -1.12 |
| 11 Month Change | -9.86% |
| 3 Month Change | 4.92% |
| 1 Year Change | -3.03% |
| 33 Year Change | -41.82% |
| 5 Year Change | n/a |
| Change since IPO | -44.83% |
Recent News & Updates
Shareholder Returns
| OTC | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | -3.0% | 4.5% | 0.7% |
| 1Y | -3.0% | 6.1% | 21.7% |
Return vs Industry: OTC underperformed the Canadian Medical Equipment industry which returned 6.1% over the past year.
Return vs Market: OTC underperformed the Canadian Market which returned 21.7% over the past year.
Price Volatility
| OTC volatility | |
|---|---|
| OTC Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 13.4% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: OTC has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: OTC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Dean Burns | ocumetics.com |
Ocumetics Technology Corp. engages in research, development, production, and sale of vision enhancement products in Canada. The company provides intraocular lenses primarily for people over 45 years of age. The company was formerly known as Quantum Blockchain Technologies Ltd.
Ocumetics Technology Corp. Fundamentals Summary
| OTC fundamental statistics | |
|---|---|
| Market cap | CA$38.33m |
| Earnings (TTM) | -CA$2.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.4x
P/E RatioIs OTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTC income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.87m |
| Earnings | -CA$2.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -35.4% |
How did OTC perform over the long term?
See historical performance and comparison